IPX203 for Parkinson's Disease
(BOOST-PD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new extended-release medication, IPX203 (Crexont®), to evaluate its effectiveness in increasing "good on time" for people with Parkinson’s disease. "Good on time" refers to periods when symptoms are well-controlled, allowing patients to go about their day without bothersome movements. The study uses a wrist device to measure the duration and effectiveness of the medication. Individuals diagnosed with Parkinson’s, who are already taking levodopa, and experience at least 2 hours a day of poor symptom control might be suitable for this trial. As a Phase 4 trial, this research aims to understand how this FDA-approved and effective treatment benefits more patients.
Will I have to stop taking my current medications?
The trial does not specify if you must stop taking your current medications, but you need to be on a stable dose of your current Parkinson's medications for at least 30 days before joining. If you use 'on demand' therapy, you must be willing to stop it during the study.
What is the safety track record for IPX203?
Research has shown that IPX203, also known as Crexont®, is generally safe for people with Parkinson's disease. One study found that taking IPX203 about three times a day for nine months was effective and usually safe. Another study demonstrated that it could help improve movement and increase "good on time," when symptoms are well-controlled. Although the treatment is considered safe, all medicines can have side effects, so discussing any concerns with a doctor is important.12345
Why are researchers enthusiastic about this study treatment?
Researchers are excited about IPX203 for Parkinson's disease because it offers a potentially more flexible and effective dosing regimen compared to current treatments. Unlike standard medications like Levodopa that often require strict dosing schedules, IPX203 allows for shorter dose intervals and higher dosing frequency, which could lead to more consistent symptom control. Plus, with the integration of the KinesiaU device, patients and doctors can objectively monitor "on-time" periods and other important parameters, potentially enhancing the overall treatment experience and outcomes. This approach aims to provide a more personalized and responsive treatment for those living with Parkinson's disease.
What is the effectiveness track record for IPX203 in treating Parkinson's Disease?
Research has shown that IPX203, also known as Crexont, may help treat Parkinson's disease. One study found that taking IPX203 about three times a day for nine months helped keep symptoms under control and was generally safe. Another study suggested that IPX203 can reduce "Off" time, when medication isn't working well, and increase "Good On" time, meaning patients have better symptom control for longer. Additionally, IPX203 has improved sleep quality, which is important for managing overall symptoms. Compared to immediate-release carbidopa-levodopa, IPX203 may provide more consistent control of movement problems, which are common in Parkinson's disease. Participants in this trial will be in an intervention arm where they convert to shorter dose intervals of Crexont (IPX203) and allow for higher dosing frequency, combined with objective monitoring using the KinesiaU device.13456
Who Is on the Research Team?
Hubert Fernandez, MD
Principal Investigator
The Cleveland Clinic
Are You a Good Fit for This Trial?
This trial is for individuals with Parkinson's Disease who are looking to improve their 'good on time'—when symptoms are well-controlled by medication. Details about specific inclusion and exclusion criteria were not provided, so interested participants should inquire further.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive IPX203 (Crexont®) with tailored dose adjustments, monitored using the KinesiaU device
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- IPX-203
Trial Overview
The study tests IPX203 (Crexont®), a new extended-release levodopa formulation, to see if it extends the duration and quality of symptom control in Parkinson's patients. Participants will wear a KinesiaU device on their wrist to monitor changes.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
The intervention arm will be patients converting to shorter dose intervals of Crexont (IPX203) and allowing for higher dosing frequency, as practiced in real-world settings, combined with objective monitoring of on-time periods and other parameters using the KinesiaU device, could reveal additional benefits of Crexont (IPX203) treatment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
The Cleveland Clinic
Lead Sponsor
Amneal Pharmaceuticals, LLC
Industry Sponsor
Citations
Safety and Efficacy of IPX203 in Parkinson Disease
Trial results suggest that treatment with IPX203 given an average of 3 times a day for 9 months provides maintained efficacy and is generally safe and well ...
Amneal Announces New Data from Phase 3 Study Showing ...
The new Phase 3 data analysis shows CREXONT's ability to significantly improve sleep, in addition to its effects on daytime PD symptoms.
IPX203 vs Immediate-Release Carbidopa-Levodopa for ...
The results of this study suggest that IPX203 vs immediate-release carbidopa-levodopa may be useful in patients with Parkinson disease and motor fluctuations.
Pharmacodynamics, Efficacy, and Safety of IPX203 in ...
IPX203 demonstrated a sustained effect to reduce Off time and improve Good On time in patients with PD and motor fluctuations. Both treatments were well ...
NCT03670953 | A Study to Evaluate the Safety and ...
A randomized controlled study to compare the safety and efficacy of IPX203 with immediate-release carbidopa-levodopa in Parkinson's disease patients with motor ...
Efficacy and Safety of IPX203 in Parkinson's Patients
IPX203 shows a significant potential in improving motor functions, reducing “off” time while increasing “good on” time.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.